Alkermes PLC (NASDAQ:ALKS) has earned an average rating of “Hold” from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $63.40.
A number of research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. ValuEngine lowered shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Barclays PLC lowered shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $66.00 to $50.00 in a research note on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the company a “buy” rating in a research note on Friday. Finally, UBS AG set a $54.00 price objective on shares of Alkermes PLC and gave the company a “hold” rating in a research note on Friday.
Alkermes PLC (NASDAQ ALKS) traded down 0.27% during midday trading on Thursday, hitting $48.76. The company had a trading volume of 895,891 shares. The stock’s market cap is $7.49 billion. The company’s 50 day moving average is $51.14 and its 200 day moving average is $54.89. Alkermes PLC has a 12-month low of $47.01 and a 12-month high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. During the same quarter last year, the business earned ($0.09) earnings per share. The business’s revenue for the quarter was up 20.6% on a year-over-year basis. On average, equities analysts anticipate that Alkermes PLC will post ($0.03) EPS for the current fiscal year.
In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $50.64, for a total value of $75,960.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of Alkermes PLC stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the transaction, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,566 shares of company stock worth $847,915. 5.34% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Crossmark Global Holdings Inc. acquired a new position in Alkermes PLC in the third quarter worth approximately $344,000. State of New Jersey Common Pension Fund D grew its position in Alkermes PLC by 55.6% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 70,000 shares of the company’s stock worth $3,559,000 after purchasing an additional 25,000 shares in the last quarter. New England Research & Management Inc. purchased a new position in Alkermes PLC during the 3rd quarter worth approximately $272,000. APG Asset Management N.V. grew its position in Alkermes PLC by 20.0% during the 3rd quarter. APG Asset Management N.V. now owns 81,038 shares of the company’s stock worth $4,120,000 after purchasing an additional 13,500 shares in the last quarter. Finally, Toronto Dominion Bank grew its position in Alkermes PLC by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 98.74% of the company’s stock.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.